Search Results

You searched for : boehringer  

CDSCO has approved Boehringer Ingelheim's Jardiance for the treatment of heart failure.

...
May 20

Boehringer Ingelheim and Invetx collaborates to advance monoclonal antibody biotherapeutics in animal health

Latest pharma news update...
Sep 29

US FDA approves Jardiance (empagliflozin) to treat adults living with heart failure with reduced ejection fraction

Latest Pharma News Update...
Aug 23

Glenmark Pharmaceuticals receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg

According to IQVIATM sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales ...
Jun 25

FDA approves first oral blood thinning medicines for children

With the approval of Pradaxa, a blood-clotting medicine, pediatric patients have a good therapeutic option to treat and prevent potentially deadly blood clots....
Jun 22

Glenmark launches Tiogiva, becoming one of the first companies in the UK to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler

Glenmark has launched Tiotropium Bromide Dry Powder Inhaler (DPI) under the brand name - Tiogiva in UK ...
Jun 15

Boehringer Ingelheim's Investigational Treatment for Schizophrenia receives FDA Breakthrough Therapy Designation

The company also announced the planned initiation of the innovative CONNEX Phase III clinical trial program assessing the safety and efficacy of BI 425809 ...
May 27

Lupin Receives Tentative Approval for Empagliflozin and Metformin Hydrochloride ER Tablets

Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, are indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type ...
Jan 07

Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules

Glenmark has received tentative approval by the United States Food & Drug Administration for Dabigatran Etexilate Capsules, the generic version of Pradaxa 1 Capsules...
Dec 21

Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME trial

...
Nov 19

New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1

New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1...
Nov 07

NIH study aims to identify promising COVID-19 treatments for larger clinical trials

Approximately 100 hospitalized volunteers will be assigned to each study arm with each of the study sites testing no more than three investigational treatments at ...
Oct 14

T-knife-Catalent sign Technology Transfer and Manufacturing Agreement for Cancer therapy

Manufacturing agreement for Autologous T-Cell Receptor-Based Cell Therapy...
Sep 24

Alembic Pharma receives USFDA tentative approval for Empagliflozin and Linagliptin tablets

Empagliflozin and Linagliptin tablets, have an estimated market size of US$ 244 million for twelve months ending June 2020...
Aug 27

Alembic Pharmaceuticals receives USFDA approval for Vardenafil Hydrochloride tablets

Alembic receives USFDA approval for their erectile dysfunction drug ...
Aug 05

Boehringer Ingelheim expands free telemedicine platform to connect veterinarians

The PetPro Tele+ platform offers setup in minutes to enable virtual veterinary visits ...
May 19

BioMed X Institute launches Rapid Antiviral Response Platform for pandemics

BioMed X is an independent research institute located on the campus of the University of Heidelberg in Germany. ...
May 18

Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio ...
May 16

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (...
Mar 03

Boehringer-Ingelheim Launches Patient-Centric MyStudyWindow Powered by Carebox

Boehringer Ingelheim offers MyStudyWindow to provide patients, families, caregivers, and doctors consistent access to information about Boehringer Ingelheim’s actively recruiting studies conducted at global ...
Feb 20

Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing

Boehringer Ingelheim's pan-KRAS program promises preclinical data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, USA...
Oct 31

INBUILD® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases1

New data showed positive effect of nintedanib on slowing decline of lung function in a broad range of fibrosing interstitial lung diseases with a progressive ...
Oct 01

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies ...
Sep 21

Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factors

Post-hoc analysis of the EMPA-REG OUTCOME® trial in adults with type 2 diabetes and established cardiovascular disease examined the cardiovascular benefits of empagliflozin ...
Sep 20

24 Matching result(s) found!

-Advertisements-




Trending Now

MAGGI Empowers 10 Women to Bring their Entrepreneurial dreams to lifeJune 13, 2024
FTCCI announced its Annual Excellence Awards and invites entries, last date is 20th June 2024June 13, 2024
Bird Flu Cases by Dr Praveen Gupta, Principle Director and Chief of Neurology, Fortis Hospital.June 13, 2024
Sova Health's $1 Million Seed Funding to Drive Gut Health InnovationJune 13, 2024
The Vital Role of Early Detection: Kevin Jonas on Battling Skin CancerJune 13, 2024
Zumutor Biologics Advances Cancer Care with Novel Immunotherapy ZM008: A First-in-Class Anti LLT1 AntibodyJune 13, 2024
HP Ghosh Hospital Unveils Innovative "Chest Tree" June 12, 2024
Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, IndiaJune 12, 2024
From the frontlines: Homeless person won over alcoholism, survived floods and defeated TBJune 12, 2024
The Role of Hormones in Obesity: Why Men and Women Gain Weight DifferentlyJune 12, 2024
Silent Killer: How a Young Mother’s Vision Loss Led to a Lung Cancer DiagnosisJune 12, 2024
TruAlt Bioenergy’s subsidiary, Leafiniti Bioenergy supplies over 1000 tons of Compressed Biogas to AG&P Pratham in just 5 monthsJune 11, 2024
Southeast Asia's Most Advanced Luxury Postpartum Centre Re'Joy Suites Opens in SingaporeJune 11, 2024
Poor Muscle Health in Obesity Can be A Major Risk Factor for Early DeathJune 11, 2024
Machine Learning Uncovers How Organ Ageing Impacts Health and LongevityJune 11, 2024
Why Education is Essential for Health and LongevityJune 11, 2024
New Study Reveals Antidepressant Withdrawal Symptoms Less Common but Still SignificantJune 10, 2024
Why Lowering Salt Intake Might Help Your Skin: Key Findings from UCSF StudyJune 10, 2024
Exploring AI's Potential: I&B Ministry's Seminar on Jobs and Healthcare AdvancementsJune 10, 2024
Deeply saddened by the passing away of Sri Ramoji Rao GaruJune 08, 2024